Prisca Honoré
AbbVie (United States)(US)
Publications by Year
Research Areas
Pain Mechanisms and Treatments, Neuropeptides and Animal Physiology, Ion channel regulation and function, Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases
Most-Cited Works
- → Inhibition of Hyperalgesia by Ablation of Lamina I Spinal Neurons Expressing the Substance P Receptor(1997)632 cited
- → Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons(2000)581 cited
- → A-803467, a potent and selective Na v 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat(2007)519 cited
- → Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain(1999)506 cited
- → Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord(2000)497 cited
- → A-317491, a novel potent and selective non-nucleotide antagonist of P2X 3 and P2X 2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat(2002)459 cited
- → Transmission of Chronic Nociception by Spinal Neurons Expressing the Substance P Receptor(1999)443 cited
- → A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat(2006)403 cited
- → TRPV1 Receptors in the CNS Play a Key Role in Broad-Spectrum Analgesia of TRPV1 Antagonists(2006)311 cited
- → A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats(2005)254 cited